Pancreatic cancer: from bench to 5-year survival
- PMID: 16868475
- DOI: 10.1097/01.mpa.0000229010.62538.f2
Pancreatic cancer: from bench to 5-year survival
Abstract
Pancreatic ductal adenocarcinoma is one of the most aggressive human malignancies, with an overall 5-year survival rate of less than 4%. On the molecular level, an increasing number of genetic and epigenetic alterations have been discovered, with a particular focus on growth factors and related pathways. Small-molecule tyrosine kinase inhibitors, antibodies, and other approaches have been developed in recent years to target these signal transduction pathways, and first clinical trials show encouraging results. In addition, molecular alterations have been identified that enable the cancer cells to invade the perineurium and the retroperitoneal space, thus explaining at least in part the high rate of local recurrence and the severe pain syndrome. Technically, pancreatic surgery has advanced, with acceptable morbidity and mortality rates in high-volume centers. Randomized controlled trials are increasingly carried out to define the best palliative and adjuvant therapy for this disease. Translational research combined with clinical trials will hopefully lead to improved survival and better quality of life for pancreatic cancer patients in the future.
Similar articles
-
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.Ann Surg. 2019 Mar;269(3):520-529. doi: 10.1097/SLA.0000000000002557. Ann Surg. 2019. PMID: 29068800 Clinical Trial.
-
[Treatment of pancreatic cancer--surgical point of view].Gan To Kagaku Ryoho. 2007 Jul;34(7):993-6. Gan To Kagaku Ryoho. 2007. PMID: 17637533 Review. Japanese.
-
[Surgery of malignant pancreatic tumors].Radiologe. 2009 Feb;49(2):137-43. doi: 10.1007/s00117-008-1752-4. Radiologe. 2009. PMID: 19153706 Review. German.
-
[New aspects of surgery for pancreatic cancer. Principles, results and evidence].Pathologe. 2012 Nov;33 Suppl 2:258-65. doi: 10.1007/s00292-012-1639-z. Pathologe. 2012. PMID: 23108784 Review. German.
-
Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.Saudi J Gastroenterol. 2012 Mar-Apr;18(2):118-21. doi: 10.4103/1319-3767.93815. Saudi J Gastroenterol. 2012. PMID: 22421717 Free PMC article.
Cited by
-
Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer.Mol Biol Rep. 2013 Dec;40(12):6579-85. doi: 10.1007/s11033-013-2766-1. Epub 2013 Oct 18. Mol Biol Rep. 2013. PMID: 24135803
-
Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613.Ann Transl Med. 2014 Sep;2(9):91. doi: 10.3978/j.issn.2305-5839.2014.05.08. Ann Transl Med. 2014. PMID: 25405166 Free PMC article.
-
Pancreatic adenocarcinoma: Outstanding problems.World J Gastrointest Surg. 2012 May 27;4(5):104-13. doi: 10.4240/wjgs.v4.i5.104. World J Gastrointest Surg. 2012. PMID: 22655124 Free PMC article.
-
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.Int J Pharm. 2011 May 16;409(1-2):278-88. doi: 10.1016/j.ijpharm.2011.02.037. Epub 2011 Mar 1. Int J Pharm. 2011. PMID: 21371545 Free PMC article.
-
Survival Outcomes Among Pancreatic Cancer Patients at Kenyatta National Hospital.J Gastrointest Cancer. 2022 Dec;53(4):958-964. doi: 10.1007/s12029-021-00723-w. Epub 2021 Oct 3. J Gastrointest Cancer. 2022. PMID: 34601708
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
